230 related articles for article (PubMed ID: 19243307)
1. Ten years of rituximab in NHL.
Winter MC; Hancock BW
Expert Opin Drug Saf; 2009 Mar; 8(2):223-35. PubMed ID: 19243307
[TBL] [Abstract][Full Text] [Related]
2. Rituximab in indolent lymphomas.
Sousou T; Friedberg J
Semin Hematol; 2010 Apr; 47(2):133-42. PubMed ID: 20350660
[TBL] [Abstract][Full Text] [Related]
3. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
Palanca-Wessels MC; Czuczman M; Salles G; Assouline S; Sehn LH; Flinn I; Patel MR; Sangha R; Hagenbeek A; Advani R; Tilly H; Casasnovas O; Press OW; Yalamanchili S; Kahn R; Dere RC; Lu D; Jones S; Jones C; Chu YW; Morschhauser F
Lancet Oncol; 2015 Jun; 16(6):704-15. PubMed ID: 25925619
[TBL] [Abstract][Full Text] [Related]
4. Spotlight on rituximab in non-Hodgkin lymphoma and chronic lymphocytic leukemia.
Cvetković RS; Perry CM
BioDrugs; 2006; 20(4):253-7. PubMed ID: 16831024
[TBL] [Abstract][Full Text] [Related]
5. Rituximab therapy for indolent non-Hodgkin's lymphoma.
Hagenbeek A; Czuczman MS; Ghielmini M; Herold M; Kimby E; Solal-Céligny P; Unterhalt M
Anticancer Drugs; 2002 Nov; 13 Suppl 2():S11-7. PubMed ID: 12710586
[TBL] [Abstract][Full Text] [Related]
6. Mechanism of action of rituximab.
Cerny T; Borisch B; Introna M; Johnson P; Rose AL
Anticancer Drugs; 2002 Nov; 13 Suppl 2():S3-10. PubMed ID: 12710585
[TBL] [Abstract][Full Text] [Related]
7. Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma.
Fanale MA; Younes A
Drugs; 2007; 67(3):333-50. PubMed ID: 17335294
[TBL] [Abstract][Full Text] [Related]
8. New treatment approaches to indolent non-Hodgkin's lymphoma.
Seymour JF
Semin Oncol; 2004 Feb; 31(1 Suppl 2):27-32. PubMed ID: 15042532
[TBL] [Abstract][Full Text] [Related]
9. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
Marcus R; Hagenbeek A
Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
[TBL] [Abstract][Full Text] [Related]
10. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Cvetković RS; Perry CM
Drugs; 2006; 66(6):791-820. PubMed ID: 16706552
[TBL] [Abstract][Full Text] [Related]
11. Monoclonal antibodies for the treatment of hematologic malignancies: clinical trials in Japan.
Tobinai K
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S90-6. PubMed ID: 12819934
[TBL] [Abstract][Full Text] [Related]
12. Increasing treatment options in indolent non-Hodgkin's lymphoma.
Solal-Céligny P
Semin Oncol; 2002 Apr; 29(2 Suppl 6):2-6. PubMed ID: 12040527
[TBL] [Abstract][Full Text] [Related]
13. A molecular perspective on rituximab: A monoclonal antibody for B cell non Hodgkin lymphoma and other affections.
Seyfizadeh N; Seyfizadeh N; Hasenkamp J; Huerta-Yepez S
Crit Rev Oncol Hematol; 2016 Jan; 97():275-90. PubMed ID: 26443686
[TBL] [Abstract][Full Text] [Related]
14. Effective immunochemotherapy for aggressive non-Hodgkin's lymphoma.
Coiffier B
Semin Oncol; 2004 Feb; 31(1 Suppl 2):7-11. PubMed ID: 15042528
[TBL] [Abstract][Full Text] [Related]
15. [Rituximab].
Okamoto R; Maeda Y; Sasaki T
Gan To Kagaku Ryoho; 2003 Aug; 30(8):1085-93. PubMed ID: 12938262
[TBL] [Abstract][Full Text] [Related]
16. Immunochemotherapy in indolent non-Hodgkin's lymphoma.
Czuczman MS
Semin Oncol; 2002 Apr; 29(2 Suppl 6):11-7. PubMed ID: 12040529
[TBL] [Abstract][Full Text] [Related]
17. Aggressive lymphoma: improving treatment outcome with rituximab.
Coiffier B; Pfreundschuh M; Stahel R; Vose J; Zinzani PL
Anticancer Drugs; 2002 Nov; 13 Suppl 2():S43-50. PubMed ID: 12710590
[TBL] [Abstract][Full Text] [Related]
18. Targeting CD20 in follicular NHL: novel anti-CD20 therapies, antibody engineering, and the use of radioimmunoconjugates.
Leonard JP
Hematology Am Soc Hematol Educ Program; 2005; ():335-9. PubMed ID: 16304400
[TBL] [Abstract][Full Text] [Related]
19. Rituximab: an innovative therapy for non-Hodgkin's lymphoma.
Wood AM
Am J Health Syst Pharm; 2001 Feb; 58(3):215-29; quiz 230-2. PubMed ID: 11217177
[TBL] [Abstract][Full Text] [Related]
20. Clinical trials of a mouse-human chimeric anti-CD20 monoclonal antibody (rituximab) for B cell non-Hodgkin's lymphoma in Japan.
Tobinai K
Cancer Chemother Pharmacol; 2001 Aug; 48 Suppl 1():S85-90. PubMed ID: 11587374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]